Compass Therapeutics, Inc. Stock OTC Markets
Equities
CMPX
US20454B1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.55 USD | -10.80% | +32.67% | -.--% |
04-25 | Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment | MT |
04-25 | Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment | DJ |
Sales 2024 * | - | Sales 2025 * | 11.19M 15.33M | Capitalization | 216M 296M |
---|---|---|---|---|---|
Net income 2024 * | -66M -90.45M | Net income 2025 * | -79M -108M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 19.3 x |
P/E ratio 2024 * |
-3.24
x | P/E ratio 2025 * |
-3.12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.56% |
1 day | -10.80% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 16-12-31 | |
Thomas Schuetz
FOU | Founder | 63 | 13-12-31 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 23-04-20 |
Mary Gray
BRD | Director/Board Member | 71 | 22-04-24 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 22-04-24 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.46% | 22.25B | |
-14.77% | 21.68B | |
-8.52% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- CMPX Stock
- CMPX Stock